

In Silico Design & Development of Some Selected Flavonols Against Beta-Glucuronidase Inhibitory Activity

Sovan Pattanaik^{1,*}, Sudam Chandra Si¹, Sudhanshu Sekhar Rout¹, Anindya Bose¹ and Siva Shankar Nayak²

¹School of Pharmaceutical Sciences, Siksha 'O'Anusandhan University, Bhubaneswar, Odisha-751003, India

²Siddhi Vinayaka Institute of Technology & Sciences, Bilaspur, Chhattisgarh-495001, India

Abstract: Drug discovery process develops faster due to more advances in computational techniques. The protein ligand interaction well predicted due to the *in-silico* approach study. The present investigation focused towards the development of lead structure for treatment of hepatic disorders. An increase in serum acid hydrolase, including β -glucuronidase has been reported in numbers of pathological conditions such as arthritis, renal diseases and epilepsies. Enhancement of this enzyme β -glucuronidase in blood has been found to correlate significantly with liver damage. β -glucuronidase inhibitor is a novel approach which is different from the available hepatoprotective drug therapies.

Method: The current study is based on *in-silico* ligand screening and *in-vitro* estimation of the three flavonols [Naringenin, Quercetin and 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one] compounds with enzyme β -glucuronidase. Molecular docking software Py Rex and Py Mol was used to dock the selected ligand in the binding site of the crystal structure of protein.

Results: Docking results are based on the least binding energy of the selected flavonols compounds. Further attempt has been made towards *in-vitro* estimation of this enzyme with those selected compounds. The binding affinity with existence of hydrogen bonds leads to find out the mechanism which was well correlated with the findings of *in-vitro* inhibitory activity.

Conclusion: The result outcome of the binding orientation of 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one linked with the active amino acid residue of the protein and the binding affinity leads to find out the mechanism for its potential *in-vitro* inhibitory activity.

Keywords: Protein ligand, β -glucuronidase, serum acid, Chromen, binding affinity.

INTRODUCTION

Advances in computational techniques have enabled virtual screening to have a positive impact on the drug discovery process. The majority of biological processes are well-known through protein ligand interactions [1]. The three dimensional structure of the protein-ligand composite could be serve as a considerable source understanding the way of proteins interact with another and perform biological functions. Virtual Screening based studies on molecular level have become an integral part of many modern structure-based discovery efforts [2]. An advantage of this technique is that based on the predicted binding affinity data. Therefore activities can be quantified in a biochemical assay thereby reducing the time and expenditure in identifying new leads [3].

Flavonols in particular to Quercetin and Naringenin are continuously discussed on an account of their diverse biological properties. These flavonols and its derivatives are present in fruits, vegetables and leaves and are reported to have effective with several

bioactivities including the anti-viral, anti-bacterial, anti-carcinogenic and anti-inflammatory effects, rheumatism, nephrotoxicity, arthritis, urinary disorders, analgesic and the free radical scavenging activity [4-5]. The antioxidant and hepatoprotective activities of class of flavonoids cited in the literature make these compounds attractive for scientific enquiry, for further backbone derivatization and screening as novel therapeutic agents [6-7].

Lysosomes play an important role in cell death and tissue damage. They release hydrolytic enzymes that cause auto-digestion of cellular contents. Lysosomal membrane plays a vital role in maintaining the integrity of the cell. β -Glucuronidase present in animals and has been shown to be a typical lysosomal enzyme catalyzes the hydrolysis of β -glucuronidase conjugates of exogenous and endogenous compounds produced in the body [8]. The increase level of β -glucuronidase enzyme in blood has been found in variety of pathological conditions [9]. Furthermore, enhanced activity of this enzyme β -glucuronidase in blood has been found to correlate significantly with liver damage [10-11]. This enzyme also increased in liver cancer [12]. These findings depict that design and development of specific inhibitors of β -glucuronidase has great pharmacological importance.

*Address correspondence to this author at the School of Pharmaceutical Sciences, Siksha 'O'Anusandhan University, At- Kalinga Nagar, Land mark- Near SUM Hospital, Bhubaneswar, Odisha, Pin-751003, India; Tel: 09437180498, 06746510751; E-mail: sovan.sps@gmail.com

In considering to the above facts an attempt has been made to predict the binding mode analysis of the atoms of the compounds [Naringenin, Quercetin and isolated fraction of F3 *i.e.* 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one] reported previously [13] and involved amino acid in the protein responsible for enhancement disease related activity [14].

METHODS

Preparation of Protein

The enzyme β -glucuronidase was obtained from the RCSB Protein Data Bank with PDB ID 1BHG [14-15]. All water molecules were removed and Polar Hydrogen atoms were added to the enzyme structure. The 3D cartoon structure of the protein 1BHG is shown in the Figure 1.

Preparation of Ligands

The analogues of three compounds were identified from Pubchem compound database. The search parameters were set at 95% similarity subjected to Lipinski rule of five resulting with these compounds [16-17]. The ligands were generated and three dimensional optimizations were done and then saved in mol file. The small-molecule topology generator Dundee PRODRG2 server is used for ligand optimization, a tool for high-throughput crystallography of protein-ligand complexes which takes input from existing coordinates

or various two-dimensional formats and automatically generates coordinates and molecular topologies suitable for X-ray refinement of protein-ligand complexes. Molecular properties were calculated using Mol soft online server (<http://molsoft.com/mprop/>).

Docking Software

Molecular Graphics Laboratory (MGL tools-1.5.4) was used for docking preparation and Auto dock Vina was used for binding energy calculations. Auto dock performs the docking of ligand to a set of grids (pre calculated by auto grid) describing the target protein. The energy grid was performed based on Lamarckian genetic algorithm [18]. Virtual analysis of docking site was analyzed by PyRx and PyMol (version 1.4.0 and build 8.14.10.2230).

Analysis and Visualization of Interactions in Docked Complexes

The binding interactions in the docked complexes obtained by Auto dock vina were analyzed by PyMol software (Open Bable). The binding sites was set inside a restriction sphere of radius 78, 50, 84 Å^o (X, Y, Z respectively) using vina wizard for docking analysis and were designed such that the entire ligand binding region was included within the GRID. Docking analysis of 1BHG with the QDs & NDs was carried out using Auto dock Vina. Throughout the docking study the macromolecule was kept as rigid and ligand molecules were flexible [19]. The best pose of each compound




Figure 1: Structure of outer membrane protein of 1BHG (Human β -Glucuronidase at 2.6 Å^o Resolution) obtained from RCSB Protein Data Bank online server and modify pymol analysis software.

Table 1: Ligand Parameters of Compounds Used to Satisfy Lipinski's Rule of Five for Docking Analysis

Si no	Ligand	ID	Molecular formula	Molecular weight	xLogP3	HBD	HBA
1.	Naringenin	439246	C ₁₅ H ₁₂ O ₅	272.2527	2.4	3	5
2.	Quercetin	5280343	C ₁₅ H ₁₀ O ₇	302.2357	1.5	5	7
3.	Quercetin derivative 2- (3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4-one	9818879	C ₁₇ H ₁₄ O ₇	330.2888	1.6	4	7

N.B. HBD: Hydrogen bond donor, HBA: Hydrogen bond acceptor.

Table 2: Binding Affinity (Kcal/mol) of 1BHG with Selected Ligands

SI No.	ID	No of hydrogen bonds	Binding affinity (Kcal/mol)	Amino Acid Residues Involved
1	439246	0	-7.6	NA
2	5280343	1	-7.8	ASN81
3	9818879	8	-8.3	GLU451, GLU520, TYR508, ARG600, PHE206, ASN450

NA: Not active.

was selected for the subsequent ligand protein interaction energy analysis.

In- Vitro Analysis for Estimation of Inhibitory Potency of β -Glucuronidase Activity

In this assay three compounds Quercetin, Naringenin and 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4-one was selected to determine the inhibition potency of β -glucuronidase enzyme, by measuring the absorbance at 405 nm. The total reaction mixture 2.5ml consisted of 1.85ml of 0.4mM Phenolphthalein-mono- β -glucuronic acid, tested compounds (50, 100, 150, 200, 250 μ g/ml) of 0.05ml in methanol and 0.1ml of enzyme solution (2.0 Fishman unit/ml *Escherichia coli* f3-glucuronidase) for 60 min at 37°C and pH 6.8 [20]. Then the reaction was terminated by addition 0.5 ml of 1M sodium hydroxide at pH 11. A development of pink color was measured at 400 nm by UV spectrophotometer. 0.5 ml methanol only was taken control for this β -glucuronidase enzyme estimation.

$$(\%) \text{ of } \beta\text{-glucuronidase enzyme scavenging activity} = \frac{[(\text{Abs}_{\text{control}} - \text{Abs}_{\text{test}}) / (\text{Abs}_{\text{control}})] \times 100}{}$$

Where $\text{Abs}_{\text{control}}$ is the absorbance of β -glucuronidase enzyme+methanol; $\text{Abs}_{\text{sample}}$ is the absorbance of β -glucuronidase enzyme +test sample.

Absorbance of the control solution (after 30 minutes) = 0.16



RESULTS

The ligand considered as a drug when that satisfy Lipinski's Rule of Five for docking analysis which was depicted in Table 1. Three numbers of flavonols showed their Hydrogen bond donor (HBD), Hydrogen bond acceptor (HBA) as well as Log P value which were help to predict the character drug likingness of those selected ligand derivatives. Further, Table 2 showed the binding affinity of those selected ligand with the isolated protein (1BHG) involved in related disease. The characteristic of interaction involved numbers of hydrogen atoms, binding affinity expressed in Kcal/mol and amino acid residue involved. The result of the study find the compound ID 9818879 i.e. (2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one.) with HBD = 4 and HBA = 7 along with 8 numbers of hydrogen bonds, - 8.3 Kcal/mol of binding affinity. The predicted binding interaction was showed in Figure 3c which reflected green dash lines towards various involved amino acids in the interactions as follows GLU451, GLU520, TYR508, ARG600, PHE206, ASN450. Whereas Figure 3b showed only one amino acids in the interactions ASN81 of protein 1BHG with Quercetin and Figure 3a showed no interaction of Naringenin with amino acids of the protein 1BHG.


The screening of the three flavonols derivatives (Naringenin, Quercetin and 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one) compounds, were subjected for estimation of inhibitory

Table 3: Representation of Absorbance and β -Glucuronidase Inhibition (%) of Different Compounds at Different Concentrations after 60 Minute of Incubation

Tested compounds	Conc. ($\mu\text{g/ml}$)	Absorbance of the sample after incubation	(%) of inhibition of β -glucuronidase activity = $\frac{[(\text{Abs}_{\text{control}} - \text{Abs}_{\text{test}}) / (\text{Abs}_{\text{control}})] \times 100}$	$Y=mx+c$, R^2 , IC_{50} ($\mu\text{g/ml}$)
Quercetin	50	0.1	37.2 \pm 2.94	$Y=0.194x\pm 27.39$, $R^2=0.972$, $\text{IC}_{50}=116.54$
	100	0.089	44.4 \pm 1.68	
	150	0.067	58.3 \pm 4.84	
	200	0.49	69.41 \pm 3.33	
	250	0.043	73.2 \pm 7.81	
Naringenin	50	0.14	10.1 \pm 2.47	$Y=0.136x\pm 7.55$, $R^2=0.905$, $\text{IC}_{50}=312.11$
	100	0.12	24.6 \pm 5.2	
	150	0.11	31.56 \pm 3.64	
	200	0.105	34.35 \pm 4.44	
	250	0.098	39.26 \pm 5.24	
2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4-one	50	0.065	59.3 \pm 9.24	$Y=0.223x\pm 48.22$, $R^2=0.948$, $\text{IC}_{50}=7.98$
	100	0.052	67.2 \pm 8.66	
	150	0.025	84.3 \pm 10.24	
	200	0.003	98.4 \pm 3.21	
	250	0.001	99.6 \pm 6.24	

**a****b**

(Figure 2). Continued.




c


Figure 2: a: Graph representing % of β -glucuronidase Inhibition Vs Concentration of Naringenin.

b: Graph representing % of β -glucuronidase Inhibition Vs Concentration of Quercetin.

c: Graph representing % of β -glucuronidase Inhibition Vs Concentration of 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one.



a



b

(Figure 3). Continued.




Figure 3: a: Predicted Bonded interaction (Green dashed lines) between Naringenin and 1BHG.

b: Predicted Bonded interaction (Green dashed lines) between Quercetin and ASN81 of 1BHG.

c: Predicted Bonded interaction (Green dashed lines) between ID 9818879 (2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one.) and GLU 451, GLU520, TYR508, ARG600, PHE206, ASN450 of 1BHG.

potency of β -glucuronidase activity showed that the compound 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one exhibited excellent activity with an IC_{50} value 7.98 μ g/ ml which was 14 times more potent than the compound Quercetin (IC_{50} = 116.54 μ g/ ml). Similarly, Naringenin exhibited poor activity with an IC_{50} value 312.11 μ g/ ml which was 2 times less potent than the compound Quercetin and 40 times less potent than the compound 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one.

DISCUSSION

In silico approach provides an additional validation for the experimental findings by investigation through binding mode of flavonols derivatives. The previously finding report suggest the modelled substrate-bound structure of human β -D-glucuronidase showed that the glycoside bond of p-nitrophenyl β -glucuronide was linked towards the residue Glu451 (acid/base catalyst) and Glu540 (nucleophilic residue) [21]. This is further conformed that this two residue might be considered as the active site for β -D-glucuronidase. The result outcome of the binding orientation of 2-(3, 4-Dihydroxy Phenyl)-7-Hydroxy-3-(2-Hydroxy Ethoxy) 4-H-Chromen-4one linked with the active amino acid residue of the protein (Glu540 and Glu541) and the binding affinity (- 8.3) with existence of 8 numbers of hydrogen bonds which leads to find out the mechanism for its potential *in-vitro* inhibitory activity where as the lesser binding orientation of Quercetin and absence of

binding orientation in Naringenin was the reason for lower potential inhibitory activity.

CONFLICT OF INTEREST STATEMENT

We declare that we have no conflict of interest.

REFERENCE

- [1] Pattanaik S, Panda J, Sahu PK, Banerjee MB, Rout SS. Synthesis characterization and biological evaluation of bidentate ligands (Reduced Schiff's base) with metals of copper, nickel and Zinc complexes. *Rasayan J of Chemistry* 2006; 5: 136-141.
- [2] Paul D. Structure-based virtual screening: an overview. *DDT* 2002; 720: 1047-1055.
- [3] Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. *J Mol Biol* 1996; 261: 470-489. <http://dx.doi.org/10.1006/jmbi.1996.0477>
- [4] Verschoyle RD, Steward WP, Gescher AJ. Putative cancer chemo preventive agents of dietary origin-how safe are they? *Nature Cancer* 2007; 59: 152-162.
- [5] Rout SS, Pattanaik S, Si SC, Pal A, Sahoo RN, Mohanty P. Anti-Nociceptive activities of complexes of Naringin with CO (II) metal ions. *Int J Pharm Pharm. Sci* 2013; 5: 972-975.
- [6] Rietjens IM, Boersma MG, van der Woude H, Jeurissen SM, Schutte ME, Alink GM. Flavonoids and alkenylbenzenes: mechanisms of mutagenic action and carcinogenic risk. *Mutat Res* 2005; 574: 124-138. <http://dx.doi.org/10.1016/j.mrfmmm.2005.01.028>
- [7] Pattanaik S, Si SC, Rout SS, Nayak SS. Evaluation of hepatoprotective and lipid peroxidation activity of the plant *Crataeva magna* Buch Ham (Capparidaceae). *Der Pharmacia Lettre* 2013; 5: 333-337.
- [8] Stahl PD, Fishman WH. β -D-glucuronidase. In: *Method of Enzymatic Analysis*. (Ed. Bergmeyer HU), 3rd ed., Weinheim, Verlag Chemie 1984; p. 246-256.

- [9] Pineda EP, Goldberg JA, Banks BM, Rutenburg AM. The significance of serum β -glucuronidase activity in patients with liver disease. *Gastroenterology* 1959; 36: 202-213.
- [10] Mills GT, Smith EEB. The 3-glucuronidase activity of chemically induced rat hepatoma. *Science* 1951; 114: 690-692.
<http://dx.doi.org/10.1126/science.114.2974.690>
- [11] Levy GA, Kerr LMH, Campbell JC. β -Glucuronidase and cell proliferation. *Biochem J* 1948; 42: 462-468.
- [12] Mills GT, Paul J, Smith EE. Studies in beta-glucuronidase. III. The influence of age, partial hepatectomy and other factors in the β -glucuronidase activity in rat liver. *Biochem J* 1953; 53: 245-253.
- [13] Pattanaik S, Si SC, Pal A, Nayak SS. Evaluation of hepatoprotective activity and isolation of 2-(3, 4-dihydroxy phenyl)-7-hydroxy-3-(2-hydroxy ethoxy) 4-H-chromen-4-one from column fractions of leaves of the extract of *Crataeva magna*. *Int. J Phytomedicine* 2013; 5: 452-459.
- [14] Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. *Nucleic Acid Res* 2000; 28: 235-242.
<http://dx.doi.org/10.1093/nar/28.1.235>
- [15] Jain S, Drendel WB, Chen JW, Mathews FS, Sly WS, Grub JH. Structure of beta-glucuronidase reveals lysosomal targeting and active site motifs. *Nat. Str. Biol* 1996; 3: 375-381.
<http://dx.doi.org/10.1038/nsb0496-375>
- [16] Lipinski CA. Lead- and drug-like compounds. *Drug Discov Today Technol* 2004; 1: 337-341.
<http://dx.doi.org/10.1016/j.ddtec.2004.11.007>
- [17] Lipinski CA, Lombardo F, Doming BV, Feenay PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 2001; 46: 3-26.
[http://dx.doi.org/10.1016/S0169-409X\(00\)00129-0](http://dx.doi.org/10.1016/S0169-409X(00)00129-0)
- [18] Kumar DB, Kumar PV, Bhubaneswaran SP, Mitra A. Advanced drug designing softwares and their application in medical research. *Int J Pharm Pharm Sci* 2010; 2: 16-18.
- [19] Daisy P, Nivedha RP, Bakiya RH. In silico drug designing approach for biotin protein ligase of *Mycobacterium tuberculosis*. *Asian J Pharm Clin Res* 2013; 6: 103-107
- [20] Sekikawa C, Kurihara H, Goto K, Takahashi K. Inhibition of beta-Glucuronidase by Extracts of *Chondria crassicaulis*. *Bull Fish Sci Hokkaido Univ* 2002; 53: 27-30.
- [21] Khan KM, Rahim F, Halim SA, Taha M, Khana M, Perveen S, Zaheer-ul-Haq, Msaik MA, Choudhary MI. Synthesis of novel inhibitors of beta-glucuronidase based on benzothiazole skeleton and study of their binding affinity by molecular docking. *Bioorganic & Medicinal Chemistry* 2011; 19: 4286-4294.
<http://dx.doi.org/10.1016/j.bmc.2011.05.052>